Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year High – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high on Thursday . The stock traded as high as $110.11 and last traded at $109.7620, with a volume of 261296 shares. The stock had previously closed at $104.09.

Analyst Upgrades and Downgrades

DNTH has been the subject of several recent analyst reports. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush lifted their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Price Performance

The firm has a market cap of $5.95 billion, a P/E ratio of -26.36 and a beta of 1.20. The company’s 50 day moving average is $91.76 and its two-hundred day moving average is $77.61.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after acquiring an additional 6,323 shares in the last quarter. Invesco Ltd. boosted its position in shares of Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after acquiring an additional 4,962 shares in the last quarter. Alliancebernstein L.P. increased its stake in Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after acquiring an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter valued at about $27,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.